English & Scottish HTAs Diverge On Sanofi’s Dupixent For Rare Skin Condition

The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.

The answer is money
SMC decides whether like Sanofi's Dupixent drugs are value for money • Source: Shutterstock

Scotland’s health technology appraisal (HTA) body, the Scottish Medicines Consortium, has accepted Sanofi’s Dupixent (dupilumab) for treating prurigo nodularis, a rare and chronic skin condition, while England’s NICE has rejected the drug for this indication. Different approaches to comparators used in the studies supporting Sanofi’s submissions are one reason for the diverging decisions.

In February’s raft of recommendations on medicines to be accepted for use on the Scottish National Health Service, the SMC okayed Dupixent for treating adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU Shaping Biotech Act To Unleash SME Potential

 

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

More from Geography

EU Shaping Biotech Act To Unleash SME Potential

 

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.